CCL8: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 36: | Line 36: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 05:35, 17 March 2025
CCL8, also known as Monocyte Chemoattractant Protein 2 (MCP-2), is a chemokine of the C-C motif ligand family that plays a significant role in the immune system. It is secreted by monocytes and macrophages and is involved in the recruitment and activation of leukocytes.
Function[edit]
CCL8 is a small cytokine that belongs to the CC chemokine family. It is associated with the inflammatory response and is secreted by monocytes and macrophages. CCL8 attracts immune cells, such as monocytes, T cells, and dendritic cells to sites of tissue damage and infection. This chemokine can also stimulate the production of other proinflammatory cytokines from macrophages.
Clinical significance[edit]
CCL8 has been implicated in various diseases, including HIV and cancer. In HIV, CCL8 can act as a natural suppressor of the virus by binding to the CCR5 receptor, which is used by HIV to enter cells. In cancer, CCL8 can promote tumor growth and metastasis by attracting tumor-associated macrophages.
See also[edit]
- Chemokine
- C-C motif ligand
- Monocyte
- Macrophage
- Leukocyte
- Cytokine
- T cell
- Dendritic cell
- HIV
- Cancer
- CCR5
References[edit]
<references />
| Cell signaling: cytokines | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Cell signaling: cytokines | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Immunology | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This immunology-related article is a stub.
|
| HIV | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Overview of tumors, cancer and oncology (C00–D48, 140–239) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|


